Credit: Getty Images. The combination antibiotic consists of aztreonam, a monobactam β-lactam and avibactam, a broad-spectrum β-lactamase inhibitor. The investigational antibiotic combination ...

Please provide your email address to receive an email when new articles are posted on . Aztreonam-avibactam was well tolerated and comparable in efficacy to meropenem. Pfizer plans to start the ...

Pfizer has just completed phase 3 trials of a new antibiotic that's active against highly resistant Gram-negative infections. It's a real superbug fighter. But what took so long? Once upon a time in a ...

Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over ...

Ceftazidime/Avibactam Designated QIDP for Gram Negative Infections The FDA has designated Forest Labs' investigational drug, ceftazidime/avibactam, a Qualified ...

The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application to update the label for ceftazidime-avibactam (Avycaz, Allergan, AstraZeneca) to include clinical data from a ...

Ceftazidime-avibactam is approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections, and has activity against ...

Background: Drug-resistant Klebsiella pneumoniae infections pose a significant clinical challenge due to limited treatment options. Ceftazidime-avibactam (CAZ-AVI) is a novel β-lactam/β-lactamase ...

DUBLIN, Feb. 25, 2015 -- Actavis plc (NYSE: ACT) today announced the U.S. Food and Drug Administration (FDA) has approved AVYCAZ™ (ceftazidime-avibactam). AVYCAZ was approved for the treatment of ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...